

Summit Corporation plc
("Summit" or "the Company")

SUMMIT SHOWCASE SEGLIN TECHNOLOGY AT INTERNATIONAL IMINOSUGAR CONFERENCE

Oxford, UK, 29 June 2010, Summit Corporation plc (AIM: SUMM), announce that it presented its Seglin™ technology platform at the international scientific conference 'Iminosugars: Past, Present and Future' that was held at St John's College, Oxford, UK on 28 June 2010.

The conference reviewed the latest scientific advancements in the area of Iminosugars and included presentations from experts and key opinion leaders in the field. As pioneers of second generation Iminosugars, or Seglins, Summit showcased its innovative technology platform to an international audience from industry and academia, and highlighted the potential of Seglin™ technology as a source of new medicines to treat a range of major diseases.

Further information about the conference, including the full list of speakers, is available at www.summitplc.com. In addition, the presentations given by Summit are available on request from investors@summitplc.com

- END -

For more information, please contact:

Summit

Steven Lee, PhD
Richard Pye, PhD

Tel: +44 (0)1235 443939

Singer Capital Markets (Nominated Adviser)

Shaun Dobson / Claes Spång

Tel: +44 (0)20 3205 7500

Peckwater PR

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

About Summit

Summit is an Oxford, UK based drug discovery company with a portfolio of partner funded drug programmes and an innovative technology platform called Seglins™ for the discovery of new medicines.

Summit's partnered drug programmes require no further investment from the Company but have contractual, success-based milestones potentially worth in excess of \$160 million and sales royalties rising to a low teen percentage. Partners include leading orphan drug specialist BioMarin Pharmaceuticals (Duchenne Muscular Dystrophy programme) and the Wellcome Trust (*C. difficile* programme).

Seglin™ technology

Seglin™ technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches. Summit's internal research is currently focussed in the high value therapy areas of type II diabetes and infectious diseases and the Company will further exploit the technology's wider potential through strategic alliances.



Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.